Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Plans Dividend of $1.50

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced a dividend on Monday, July 13th. Shareholders of record on Thursday, July 23rd will be given a dividend of 1.50 per share by the specialty pharmaceutical company on Friday, July 31st. The ex-dividend date of this dividend is Thursday, July 23rd.

Cumberland Pharmaceuticals Stock Up 10.3%

Shares of Cumberland Pharmaceuticals stock opened at $6.54 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. The stock has a market capitalization of $97.97 million, a PE ratio of -13.35 and a beta of 0.09. Cumberland Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $7.36. The company has a 50-day simple moving average of $5.70 and a two-hundred day simple moving average of $4.45.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $9.13 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Institutional Trading of Cumberland Pharmaceuticals

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals during the second quarter valued at approximately $34,000. Arrowstreet Capital Limited Partnership bought a new position in Cumberland Pharmaceuticals during the first quarter valued at approximately $66,000. Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after purchasing an additional 5,326 shares during the last quarter. Marshall Wace LLP purchased a new stake in Cumberland Pharmaceuticals in the fourth quarter worth approximately $192,000. Finally, Geode Capital Management LLC grew its position in Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares during the period. 15.51% of the stock is currently owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.